Arcadia Biosciences, Inc. (RKDA)
0.1669
+0.01
(+5.50%)
USD |
NASDAQ |
Nov 05, 16:00
Arcadia Biosciences Enterprise Value : -3.814M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -3.814M |
| November 04, 2026 | -3.833M |
| November 03, 2026 | -3.840M |
| November 02, 2026 | -3.838M |
| October 30, 2026 | -3.834M |
| October 29, 2026 | -3.806M |
| October 28, 2026 | -3.833M |
| October 27, 2026 | -3.829M |
| October 26, 2026 | -3.847M |
| October 23, 2026 | -3.825M |
| October 22, 2026 | -3.825M |
| October 21, 2026 | -3.834M |
| October 20, 2026 | -3.844M |
| October 19, 2026 | -3.862M |
| October 16, 2026 | -3.818M |
| October 15, 2026 | -3.734M |
| October 14, 2026 | -3.740M |
| October 13, 2026 | -3.725M |
| October 12, 2026 | -3.685M |
| October 09, 2026 | -3.601M |
| October 08, 2026 | -3.581M |
| October 07, 2026 | -3.552M |
| October 06, 2026 | -3.528M |
| October 05, 2026 | -3.552M |
| October 02, 2026 | -3.549M |
| Date | Value |
|---|---|
| October 01, 2026 | -3.558M |
| September 30, 2026 | -3.567M |
| September 29, 2026 | -3.566M |
| September 28, 2026 | -3.506M |
| September 25, 2026 | -3.507M |
| September 24, 2026 | -3.489M |
| September 23, 2026 | -3.249M |
| September 22, 2026 | -3.201M |
| September 21, 2026 | -3.218M |
| September 18, 2026 | -3.188M |
| September 17, 2026 | -3.136M |
| September 16, 2026 | -3.174M |
| September 15, 2026 | -3.238M |
| September 14, 2026 | -3.198M |
| September 11, 2026 | -3.238M |
| September 10, 2026 | -3.190M |
| September 09, 2026 | -3.131M |
| September 08, 2026 | -3.152M |
| September 04, 2026 | -3.147M |
| September 03, 2026 | -3.149M |
| September 02, 2026 | -3.066M |
| September 01, 2026 | -3.079M |
| August 31, 2026 | -3.046M |
| August 28, 2026 | -3.022M |
| August 27, 2026 | -3.059M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moolec Science SA | -- |
| Zivo Bioscience, Inc. | 34.68M |
| PMGC Holdings, Inc. | -4.452M |
| Archer-Daniels-Midland Co. | 38.26B |
| Alico, Inc. | 305.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.266M |
| Revenue (Quarterly) | 1.443M |
| Total Expenses (Quarterly) | 7.709M |
| EPS Diluted (Quarterly) | -2.094 |
| Gross Profit Margin (Quarterly) | 43.73% |
| Profit Margin (Quarterly) | -434.2% |
| Earnings Yield | -2.73K% |
| Normalized Earnings Yield | -2210.49 |